The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats
Peptides 69:47–55, 2015
Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis
Diabetes 64(3):1046–56, 2015
The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat
European Journal of Pharmacology 741:254-263, 2014
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Journal of Clinical Investigation 124(10):4473-4488, 2014
The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat
The Journal of Pharmacology and Experimental Therapeutics 350(3):657–664, 2014
The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice
The Journal of Pharmacology and Experimental Therapeutics 350(2):353–360, 2014
The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis
American Journal of Physiolology - Endocrinology and Metabolism 303:E253-E264, 2012
Liraglutide: short-lived effect on gastric emptying – long lasting effects on body weight
Diabetes Obesity & Metabolism 14(6):531–538, 2012
Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats
Acta Pharmacologica Sinica 33:194–200, 2012